Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Day One Biopharmaceuticals, Inc. (DAWN) had Normalized Pre-Tax Income of $-30.32M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$33.91M |
|
$-30.32M |
|
$3.77M |
|
$30.14M |
|
$68.88M |
|
$-34.97M |
|
$4.65M |
|
$-30.32M |
|
|
Normalized Pre-Tax Income |
$-30.32M |
$-30.32M |
|
$-30.32M |
|
$-30.32M |
|
$-30.32M |
|
$-34.97M |
|
$-34.01M |
|
103.07M |
|
103.07M |
|
$-0.29 |
|
$-0.29 |
|
| Balance Sheet Financials | |
$494.43M |
|
$2.32M |
|
$24.61M |
|
$519.04M |
|
$51.22M |
|
-- |
|
$6.98M |
|
$58.20M |
|
$460.83M |
|
$441.22M |
|
$460.83M |
|
102.43M |
|
| Cash Flow Statement Financials | |
$-83.80M |
|
$-6.29M |
|
$0.75M |
|
$124.97M |
|
$35.62M |
|
$-89.35M |
|
$23.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
88.90% |
|
-103.14% |
|
-103.14% |
|
-- |
|
-89.42% |
|
-89.42% |
|
$-84.09M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.58 |
|
1.72 |
|
52.21 |
|
-6.58% |
|
-6.87% |
|
-5.84% |
|
-6.58% |
|
$4.50 |
|
$-0.82 |
|
$-0.81 |
|